421 related articles for article (PubMed ID: 29322842)
21.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
22. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
23. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
25. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
26. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
27. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
[TBL] [Abstract][Full Text] [Related]
28. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
30. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
31. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
32. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
[TBL] [Abstract][Full Text] [Related]
33. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
[TBL] [Abstract][Full Text] [Related]
34. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
35. Potential anti-neuroblastoma agents from Juniperus oblonga.
Qiao Y; Sunada NK; Hatada AE; Lange I; Khutsishvili M; Alizade V; Atha D; Ko'omoa-Lange DL; Borris RP
Biochem Biophys Res Commun; 2019 Aug; 516(3):733-738. PubMed ID: 31255282
[TBL] [Abstract][Full Text] [Related]
36. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
37. ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression.
Watanabe Y; Ishizuka Y; Hirano T; Nagasaki-Maeoka E; Hoshi R; Yoshizawa S; Uekusa S; Kawashima H; Sugito K; Shinohara K; Fukuda N; Nagase H; Soma M; Koshinaga T; Fujiwara K
Med Oncol; 2017 Aug; 34(9):158. PubMed ID: 28791558
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
39. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
40. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]